Last updated: August 29, 2026
Clascoterone is a topical androgen-receptor inhibitor marketed in the United States as Winlevi 1% cream by Sun Pharmaceutical Industries. The FDA approved Winlevi in August 2020 for the topical treatment of acne vulgaris in patients aged 12 years and older. The product entered the U.S. market in late 2021.
Winlevi has a differentiated mechanism and limited direct competition among branded topical acne products. Its commercial performance depends on prescription growth, payer coverage, patient copay levels, dermatologist adoption, and expansion into androgenetic alopecia. The largest potential value driver is a separate clascoterone 5% topical solution program for hair loss. That indication could materially expand the addressable market, but it remains development-stage and carries clinical, regulatory, and launch risk.
What is clascoterone and how does Winlevi work?
Clascoterone is a topical androgen-receptor inhibitor. Winlevi is formulated as a 1% cream for twice-daily application to acne-affected skin. The drug is designed to reduce androgen signaling in the skin, which can decrease sebum production and inflammatory acne activity.
The FDA approved Winlevi based on two Phase III trials involving patients with acne vulgaris. The approved label covers patients 12 years of age and older and does not restrict use by sex. The product is not an antibiotic, retinoid, hormonal contraceptive, or systemic antiandrogen.
| Attribute |
Winlevi |
| Active ingredient |
Clascoterone |
| Strength |
1% cream |
| FDA approval |
August 26, 2020 |
| Indication |
Topical treatment of acne vulgaris |
| Approved population |
Patients aged 12 years and older |
| U.S. commercial partner |
Sun Pharmaceutical Industries |
| Original developer |
Cassiopea |
| Current corporate owner of development rights |
Cosmo Pharmaceuticals through its Cassiopea subsidiary |
| Regulatory pathway |
New Drug Application |
| Product type |
Small-molecule topical drug |
The mechanism gives Winlevi a differentiated position in acne, but differentiation has not eliminated competition from low-cost generic tretinoin, adapalene, benzoyl peroxide, topical antibiotics, and oral isotretinoin.
When did Winlevi launch and who owns its commercial rights?
Sun Pharma holds the U.S. commercialization rights under an agreement originally signed with Cassiopea. Cassiopea was acquired by Cosmo Pharmaceuticals in 2020, making Cosmo the parent company behind the clascoterone program.
The commercial structure gives Sun Pharma responsibility for U.S. promotion and distribution while Cosmo retains economic participation through royalties and development-related payments. The precise economics depend on contractual terms that are not fully disclosed in public filings.
Key development and commercial milestones
| Date |
Milestone |
| 2019 |
Cassiopea and Sun Pharma entered a U.S. commercialization agreement |
| 2020 |
Cosmo completed its acquisition of Cassiopea |
| August 2020 |
FDA approved Winlevi for acne vulgaris |
| Late 2021 |
Sun Pharma launched Winlevi in the United States |
| 2022 onward |
Sun Pharma expanded dermatologist promotion and market access activity |
| 2023-2024 |
Development activity continued for clascoterone topical solution in androgenetic alopecia |
Winlevi is primarily a U.S. commercial asset. Its near-term financial trajectory therefore depends more on U.S. prescription growth and reimbursement than on international sales.
How large is the market for clascoterone?
The acne market is large, chronic, and highly fragmented. It includes adolescents, young adults, and older patients with persistent or hormonally influenced acne. Treatment is often sequential or combination-based, which allows a branded topical to compete for a place in therapy even when inexpensive generics are available.
Winlevi's most direct commercial opportunity is in patients who:
- Need a non-antibiotic topical treatment.
- Have acne associated with androgen activity.
- Cannot tolerate or do not respond adequately to retinoids or benzoyl peroxide.
- Prefer a topical option over oral hormonal therapy.
- Have insurance coverage that supports a branded dermatology product.
The product faces a substantial pricing gap against generic acne therapies. Its commercial model therefore requires dermatologist prescribing, patient persistence, and manufacturer copay support.
The larger opportunity is androgenetic alopecia. Male and female pattern hair loss affects a much larger adult population than prescription-treated acne. Existing approved therapies include topical minoxidil and oral finasteride for specified populations, while spironolactone and other products are used off label. A topical androgen-receptor inhibitor could occupy a differentiated position if Phase III data demonstrate clinically meaningful hair growth with acceptable local and systemic safety.
What is the financial trajectory for Winlevi?
Public companies do not consistently disclose a complete standalone revenue series for Winlevi. Sun Pharma reports consolidated results across its global portfolio, while Cosmo reports royalty and product-related economics under its corporate reporting structure. Public prescription data and company commentary indicate that Winlevi has been in commercial ramp-up rather than at mature peak sales.
The key financial characteristics are:
- Launch costs were front-loaded. Sun Pharma incurred sales, marketing, patient-support, and market-access expenses before the product reached scale.
- Net sales depend heavily on gross-to-net deductions. Rebates, discounts, copay assistance, returns, and distribution adjustments can materially reduce gross prescription value.
- Dermatology products can scale without hospital infrastructure, but they require sustained physician promotion.
- The royalty model gives Cosmo exposure to growth without requiring it to fund all U.S. commercial expenses.
- A successful alopecia indication would expand revenue potential well beyond the current acne franchise.
Financial drivers
| Driver |
Effect on revenue |
| Dermatologist prescription growth |
Increases new patient starts |
| Refill persistence |
Raises revenue per patient |
| Commercial insurance coverage |
Reduces abandonment |
| Copay support |
Improves conversion but increases gross-to-net deductions |
| Generic pricing pressure |
Limits pricing power |
| Indication expansion |
Creates a new patient population |
| Sales-force productivity |
Determines launch efficiency |
| Patent and regulatory protection |
Extends the period for premium pricing |
Winlevi's financial profile is more comparable to a specialty branded dermatology product than to a mass-market primary-care drug. Market penetration can be gradual because physicians often begin with generic therapies and reserve branded products for treatment-resistant or specific patient groups.
What patents protect clascoterone and Winlevi?
Winlevi's protection is expected to depend on a combination of composition, formulation, manufacturing, and method-of-use rights rather than on a single broad compound patent.
Relevant protection categories include:
- Clascoterone compositions and pharmaceutical preparations.
- Topical cream formulations containing clascoterone.
- Treatment of acne through topical androgen-receptor inhibition.
- Potentially distinct formulations for scalp delivery and androgenetic alopecia.
- Manufacturing processes and formulation stability.
Because Winlevi is a small-molecule drug, it does not receive biologic exclusivity under the Purple Book framework. Generic applicants would use the ANDA pathway and could challenge listed patents through Paragraph IV certifications.
What is the Orange Book status of Winlevi?
Winlevi is an FDA-approved small-molecule prescription drug and is subject to Orange Book patent-listing rules. The controlling source for listed patents, regulatory exclusivity, and expiration dates is the FDA's current Orange Book database.
The business risk is not limited to the earliest compound-related patent. Formulation and method-of-use patents can delay or complicate generic entry if they are properly listed and withstand litigation. At the same time, formulation patents can be narrower and more vulnerable than a broad composition-of-matter patent.
Publicly available commercial information does not establish a definitive generic launch date. The practical entry date will depend on:
- The patents listed in the Orange Book at the time of an ANDA filing.
- The scope of each Paragraph IV certification.
- Whether Sun Pharma or Cosmo initiates Hatch-Waxman litigation.
- The outcome of litigation or settlement.
- Whether the generic applicant receives a 30-month stay or secures an earlier launch path.
When could generic competition affect Winlevi?
A generic version would likely compete on price and could target the same acne population. The product's formulation, topical delivery characteristics, and clinical positioning could create development barriers, but they would not prevent an ANDA applicant from seeking approval.
Potential generic entry scenarios include:
Early challenge with litigation
An ANDA applicant files with a Paragraph IV certification before all relevant patents expire. Sun Pharma or the patent owner files suit, potentially triggering a statutory stay of FDA approval for up to 30 months, subject to statutory conditions.
Settlement with delayed launch
The parties settle the litigation and agree to a launch date before the latest patent expiration. The economic effect depends on whether the agreement includes authorized generic rights, royalty payments, or restrictions on competing formulations.
Formulation-based competition
A generic applicant challenges the active ingredient or uses a formulation that avoids some listed claims. This could produce a narrower product profile or require separate litigation.
Post-patent price erosion
After relevant patents expire, multiple ANDA-approved products could enter. Topical dermatology products often experience rapid price erosion when several generics launch, although physician loyalty and formulation tolerability can slow switching.
No widely reported public Paragraph IV litigation involving Winlevi had established a final market-entry outcome through mid-2024. That status can change as ANDA filings and Orange Book listings evolve.
What is the outlook for clascoterone in androgenetic alopecia?
The alopecia program is the principal expansion opportunity. The target is a topical clascoterone solution, generally described as a 5% formulation, for androgenetic alopecia.
A successful program would give the asset access to:
- Male pattern hair loss.
- Female pattern hair loss, subject to trial design and labeling.
- Patients seeking a non-oral treatment.
- Patients concerned about systemic antiandrogen exposure.
- Dermatology and hair-restoration practices.
The development risk is higher than in acne because hair-growth trials require longer treatment periods, objective endpoint measurement, and durable evidence of benefit. Patient expectations are also high, and the commercial market includes prescription, over-the-counter, compounded, and procedural alternatives.
The formulation could receive separate patent protection if it contains novel excipients, delivery characteristics, concentration ranges, or treatment methods. Such rights would not automatically extend the full patent life of the acne cream, but they could create a later barrier for the alopecia indication.
How does clascoterone compare with competing acne drugs?
| Product or class |
Main advantage |
Main limitation relative to Winlevi |
| Generic tretinoin |
Low cost and extensive clinical use |
Irritation and limited tolerability for some patients |
| Adapalene |
Widely available, low-cost retinoid |
Generic competition and irritation |
| Benzoyl peroxide |
Established antimicrobial and anti-inflammatory use |
Dryness, irritation, and bleaching of fabrics |
| Topical antibiotics |
Useful for inflammatory acne |
Antibiotic-resistance concerns and limited long-term use |
| Winlevi |
Non-antibiotic androgen-receptor mechanism |
High branded cost and reimbursement dependence |
| Oral isotretinoin |
Strong efficacy for severe acne |
Systemic safety monitoring and restricted use |
| Hormonal therapy |
Useful for androgen-related acne |
Population-specific and systemic treatment |
Winlevi's competitive position is strongest as an adjunct or alternative for patients whose acne is difficult to manage with generic topical therapy. Its position is weaker where payers require step therapy or where patients can obtain acceptable control with low-cost products.
What licensing deals and commercial partnerships affect clascoterone?
The main commercial agreement is the Cassiopea-Sun Pharma U.S. licensing and commercialization arrangement. Sun Pharma's role provides an established dermatology sales infrastructure, while Cosmo retains economic participation through its ownership of Cassiopea.
The partnership has two strategic effects:
- It limits Cosmo's direct U.S. commercial investment.
- It makes Winlevi's sales trajectory dependent on Sun Pharma's prioritization, promotion, and market-access execution.
The agreement also creates a potential negotiation point for future indications. Expansion into alopecia could require changes to commercial responsibilities, milestone payments, royalty economics, or geographic rights.
What manufacturing and intellectual-property barriers exist?
Clascoterone is a topical small molecule, so manufacturing barriers are lower than for complex biologics. The principal barriers are formulation consistency, active pharmaceutical ingredient supply, stability, scale-up, and demonstration of pharmaceutical equivalence.
A generic applicant must address:
- Clascoterone API sourcing.
- Cream composition and physical characteristics.
- Drug release and delivery performance.
- Stability and packaging.
- Bioequivalence or other FDA-required comparative testing.
- Patent claims covering the formulation or method of use.
These requirements can delay entry without creating permanent protection. The most durable commercial advantage would come from a broad and enforceable patent estate combined with physician adoption and patient persistence.
What is the competitive and investment outlook for clascoterone?
Clascoterone has a credible specialty dermatology position, but Winlevi's acne indication alone is unlikely to justify a large blockbuster valuation without substantial prescription growth or a major indication expansion.
The investment case has four parts:
- Acne provides an established commercial base.
- The topical androgen mechanism differentiates the product.
- Sun Pharma offers commercial scale.
- Alopecia creates a potentially much larger market.
The principal risks are branded-versus-generic pricing pressure, payer restrictions, slow dermatologist adoption, uncertain refill behavior, clinical failure in alopecia, and future ANDA litigation.
The revenue trajectory should therefore be assessed through prescription growth, net realized price, payer mix, refill rates, sales-force productivity, and development milestones rather than through gross launch sales alone.
Key Takeaways
- Clascoterone is marketed as Winlevi 1% cream for acne vulgaris in patients aged 12 and older.
- Sun Pharma commercializes Winlevi in the United States; Cosmo controls the underlying development program through Cassiopea.
- Acne provides the current revenue base, but androgenetic alopecia is the main expansion opportunity.
- Winlevi competes against inexpensive generic retinoids, benzoyl peroxide, topical antibiotics, oral isotretinoin, and hormonal therapies.
- The financial model is sensitive to insurance coverage, copay support, gross-to-net deductions, and dermatologist adoption.
- Generic entry will depend on Orange Book listings, Paragraph IV challenges, Hatch-Waxman litigation, and settlement terms.
- Winlevi is a small-molecule drug and does not receive biologic exclusivity under the Purple Book framework.
- The strongest long-term value catalyst is successful development and approval of clascoterone topical solution for androgenetic alopecia.
FAQs
Is clascoterone the same as Winlevi?
Yes. Clascoterone is the active ingredient, and Winlevi is the U.S. brand name for the 1% topical cream approved for acne vulgaris.
Is Winlevi a steroid or an antibiotic?
No. Clascoterone is a topical androgen-receptor inhibitor. Winlevi is neither a corticosteroid nor an antibiotic.
Can clascoterone treat hair loss?
Clascoterone is being developed for androgenetic alopecia, but the acne product's FDA label does not establish approval for hair loss.
Does Winlevi have biosimilar competition?
No. Winlevi is a small-molecule drug, so potential competitors would generally pursue the ANDA generic-drug pathway rather than the biosimilar pathway.
What would most increase clascoterone's value?
Approval for androgenetic alopecia would likely have the greatest effect because it could expand the addressable patient population substantially beyond acne.
References
-
U.S. Food and Drug Administration. (2020). FDA approves new treatment for acne. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-acne
-
U.S. Food and Drug Administration. (2023). Winlevi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214232s003lbl.pdf
-
Cosmo Pharmaceuticals N.V. (2023). Annual report 2022. https://www.cosmopharma.com/investors/
-
Cosmo Pharmaceuticals N.V. (2024). Annual report 2023. https://www.cosmopharma.com/investors/
-
Sun Pharmaceutical Industries Limited. (2024). Annual report 2023-24. https://www.sunpharma.com/investors
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
